Whereas high SerpinB2 was related to reduced survival in bladder cancer [34], endometrial cancer [35], and esophageal squamous cell carcinoma [36], low SerpinB2 has been associated with worse survival in breast cancer [37, 38], hepatocellular carcinoma [39], and pancreatic cancer [40]. Here, SERPINB2 is linked to urinary bladder carcinoma.